~$23–26B
Pharmaceutical market value 2026
#1
Global biologics CDMO capacity (Samsung)
~51M
Population (universal NHIS coverage)
10–14 mo
MFDS registration timeline
South Korea Pharmaceutical Market Overview
South Korea's pharmaceutical market is valued at approximately US$23–26 billion in 2026, backed by universal National Health Insurance Service (NHIS) coverage for 51 million people. HIRA (Health Insurance Review & Assessment Service) runs one of Asia's most rigorous pricing and reimbursement gatekeeping systems, with positive-list coverage and aggressive price negotiations.
The MFDS (Ministry of Food and Drug Safety) reviews registrations in 10–14 months, accepts global clinical packages with Korean bridging where needed, and runs expedited pathways for innovative and orphan drugs.
Korea's global significance is biomanufacturing: Samsung Biologics operates the world's largest biologics CDMO capacity, and Celltrion pioneered biosimilar monoclonal antibodies. Domestic innovators Yuhan (lazertinib out-licensed to J&J), Hanmi, Daewoong, HK inno.N, and GC Biopharma increasingly generate globally licensed assets, while SK Biopharmaceuticals took cenobamate to the US market directly.
Top Pharmaceutical Companies in South Korea
The following table lists the major pharmaceutical companies operating in South Korea — including local manufacturers, multinational offices, regional players, and leading distributors.
| Company | HQ |
|---|---|
| Samsung Biologics / Samsung Bioepis | South Korea |
| Celltrion | South Korea |
| Yuhan Corporation | South Korea |
| Hanmi Pharmaceutical | South Korea |
| Daewoong Pharmaceutical | South Korea |
| GC Biopharma (Green Cross) | South Korea |
| SK Biopharmaceuticals | South Korea |
| HK inno.N | South Korea |
| Chong Kun Dang (CKD) | South Korea |
| Boryung | South Korea |
| Dong-A ST | South Korea |
| Pfizer Korea | USA |
| MSD Korea | USA |
| Roche Korea | Switzerland |
| Novartis Korea | Switzerland |
| AstraZeneca Korea | UK / Sweden |
| Geo-Young | South Korea |
| Baeksang / Jeil wholesale networks | South Korea |
Planning research in South Korea?
Primary research, market access & HEOR. Proposals within 48 hours.
BioNixus market research
Commission custom South Korea fieldwork
Book a 30-minute briefing to align on MFDS pathway intelligence, stakeholder mapping, and competitive tracking for South Korea.
List of Pharmaceutical Companies in South Korea by Category
South Korea pharmaceutical companies span local manufacturers, multinational corporation offices, regional suppliers, and key distributors.
Local Manufacturers
Korean companies span biomanufacturing giants (Samsung Biologics, Celltrion), traditional leaders (Yuhan, CKD, Dong-A, Boryung), and innovation-driven players (Hanmi, SK Biopharm, HK inno.N, Daewoong, GC Biopharma) with growing global licensing income.
- ✓ Samsung Biologics / Samsung Bioepis
- ✓ Celltrion
- ✓ Yuhan Corporation
- ✓ Hanmi Pharmaceutical
- ✓ Daewoong Pharmaceutical
- ✓ GC Biopharma (Green Cross)
- ✓ SK Biopharmaceuticals
- ✓ HK inno.N
- ✓ Chong Kun Dang (CKD)
- ✓ Boryung
- ✓ Dong-A ST
Multinational Offices
MNCs hold the innovative oncology and vaccine segments, navigating HIRA's demanding positive-list reimbursement and risk-sharing agreements.
- ✓ Pfizer Korea
- ✓ MSD Korea
- ✓ Roche Korea
- ✓ Novartis Korea
- ✓ AstraZeneca Korea
Regional Players
The competitive set is domestic + global; Japanese and Chinese players participate mainly via licensing.
Distributors
Geo-Young leads a consolidated wholesale sector distributing to tertiary hospitals and ~24,000 community pharmacies.
- ✓ Geo-Young
- ✓ Baeksang / Jeil wholesale networks
Pharmaceutical Companies in South Korea: MFDS Regulatory Landscape
Ministry of Food and Drug Safety is South Korea's pharmaceutical regulator.
Regulatory Authority
Ministry of Food and Drug Safety (MFDS) oversees registration, quality control, pricing, vigilance, and import licensing.
Registration Timeline
10–14 months
Renewal Period
5 years
Pricing Model
HIRA positive-list reimbursement with price negotiation (NHIS); risk-sharing agreements for high-cost drugs
Key Registration Requirements
- ✓CTD dossier via MFDS
- ✓Korean bridging data where ethnic sensitivity indicated
- ✓Korea Marketing Authorization Holder / local entity
- ✓GMP certification incl. foreign site inspection
- ✓Korean labelling and insert
- ✓HIRA reimbursement dossier separate — economic evaluation required
Market Access Note
HIRA's cost-effectiveness assessment and NHIS price negotiation are the commercial gatekeepers — expect reference pricing against lowest-in-basket and mandatory price cuts at volume thresholds. Risk-sharing agreements (refund, expenditure-cap) enable listing of high-cost oncology and rare-disease assets.
South Korea Pharmaceutical Market Growth Drivers
Biomanufacturing Superpower
Samsung Biologics' capacity expansion and Celltrion's biosimilar pipeline anchor global biologics supply chains in Incheon.
Global Licensing Engine
Korean-origin assets (lazertinib, cenobamate, tegoprazan, fexuprazan) now generate multi-billion-dollar global deals.
Aging & Chronic Care
Korea is aging faster than any OECD country — oncology, neurology, and chronic-disease demand grows structurally.
Government Bio-Vision Investment
National bio-health strategy targets K-bio as a top export industry with R&D tax and cluster incentives.
Clinical Trial Hub
Seoul is a top-5 global clinical trial city — tertiary hospital networks accelerate enrolment and KOL influence.
Digital Health & AI Adoption
World-leading hospital informatics create rapid uptake channels for companion diagnostics and digital therapeutics.
How BioNixus Supports Pharmaceutical Companies in South Korea
BioNixus is a healthcare market research company with primary-research capability in South Korea and cross-market benchmarking against GCC, USA, and European markets. We help pharma, biotech, and medtech companies with:
Physician Surveys & KOL Mapping
Korean-language fieldwork with physicians across Big-5 Seoul tertiary hospitals and regional centres.
Market Access & HIRA Strategy
Reimbursement dossier intelligence, risk-sharing agreement benchmarking, and NHIS price negotiation modelling.
Competitive Intelligence
Tracking Korean biosimilar pipelines, licensing deals, and MNC portfolio moves.
Korea vs Global Benchmarking
Launch sequencing analysis for teams weighing Korea against Japan, China, and Western markets.
Frequently Asked Questions
What are the largest pharmaceutical companies in South Korea?
The largest Korean pharmaceutical companies in 2026 are Samsung Biologics (biologics CDMO), Celltrion (biosimilars), Yuhan, Hanmi, Daewoong, GC Biopharma, Chong Kun Dang, SK Biopharmaceuticals, HK inno.N, and Dong-A ST. Samsung Biologics is the world's largest biologics contract manufacturer.
What is the size of South Korea's pharmaceutical market?
South Korea's pharmaceutical market is valued at approximately US$23–26 billion in 2026, growing 5–6% annually, with universal NHIS insurance covering the full 51-million population.
Who regulates pharmaceuticals in South Korea?
The MFDS (Ministry of Food and Drug Safety) handles registration in 10–14 months. Reimbursement is separate: HIRA assesses cost-effectiveness and the NHIS negotiates price — the true commercial gatekeepers.
Why is Korea important for global biologics?
Samsung Biologics operates the world's largest biologics CDMO capacity and manufactures for most top-20 global pharma companies, while Celltrion and Samsung Bioepis pioneered biosimilar monoclonal antibodies. The Songdo/Incheon cluster is a global biomanufacturing hub.
How does drug reimbursement work in Korea?
Korea uses a positive list: after MFDS approval, manufacturers submit a HIRA reimbursement dossier with economic evaluation, then negotiate price with NHIS. High-cost drugs increasingly list through risk-sharing agreements (refunds or expenditure caps). Prices face cuts at volume-growth thresholds.
Can foreign companies run trials and launch in Korea easily?
Yes — Seoul is a top global clinical trial hub with fast enrolment in Big-5 tertiary hospitals. MFDS accepts global packages (sometimes with Korean bridging), and a local MAH entity or partner handles registration and distribution.
Data Sources & Methodology
This guide aggregates publicly available information from:
- MFDS — Ministry of Food and Drug Safety
- HIRA reimbursement decisions and NHIS negotiations
- KPBMA (Korea Pharmaceutical and Bio-Pharma Manufacturers Association)
- Company filings (KRX-listed manufacturers)
- BioNixus proprietary research (Korea & Asia, 2024–2026)
Company lists are editorial snapshots, not endorsements; market sizes are BioNixus estimate ranges synthesised from regulator and industry sources. For customised market intelligence on South Korea, contact our team.